Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research note published on Sunday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Price Performance

Senseonics stock opened at $0.30 on Friday. Senseonics has a one year low of $0.28 and a one year high of $0.75. The business has a fifty day moving average price of $0.34 and a 200-day moving average price of $0.39. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The firm has a market capitalization of $179.49 million, a P/E ratio of -2.34 and a beta of 0.79.

Institutional Investors Weigh In On Senseonics

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in shares of Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after buying an additional 179,103 shares during the period. FMR LLC increased its holdings in Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares during the period. GSA Capital Partners LLP purchased a new position in Senseonics during the 3rd quarter valued at about $117,000. Symmetry Partners LLC purchased a new position in Senseonics during the 3rd quarter valued at about $164,000. Finally, Cubist Systematic Strategies LLC increased its holdings in Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the period. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.